HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 Plaintiffs May Turn Sights On Cosmetics With Acrylamide Actions Halted

Executive Summary

A federal court decision pending Ninth Circuit appeal, regarding acrylamide use in food, could signal a new defense option for companies facing Prop 65 claims, Greenberg Traurig attorney Will Wagner says. At the same time, it could lead to heavier plaintiff scrutiny of non-food categories such as cosmetics.

You may also be interested in...



Dismissal Of TiO2 Prop 65 Case Offers Lessons, Renewed Hope For Industry

A legal win for industry in California Prop 65 litigation targeting titanium dioxide-containing cosmetics illustrates the importance of getting involved early in the listing process and challenging the factual basis for exposure claims. Morrison & Foerster attorney Michael Steel discusses the case and its takeaways.

Cosmetics Firms To Phase Out Cocamide DEA Under Prop 65 Settlements

At a time when California regulators are considering amendments to Proposition 65 to stem a rising tide of related lawsuits, 14 personal-care manufacturers and retailers have settled suits filed by the Center for Environmental Health for violating the regulation and failing to properly warn consumers about the use of cocamide DEA in products.

Cosmetics Firms Held “Hostage” By Prop 65 Litigators; Law Changes Possible

Proposition 65 lawsuits have increased for the cosmetics industry with the expiration of a grace period for new ingredients added to California’s list of substances linked to cancer or reproductive toxicity. Attorneys from Edwards Wildman offer perspective on the issue and its impact on industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel